Zhejiang Taimei Medical Technology Co (FRA:A2V) EBIT: €-6.03 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:A2V Zhejiang Taimei Medical Technology Co Ltd FRA:A2V
11 GF Score
Price €0.60
! 4 Warning Signs
View Full Analysis

What is Zhejiang Taimei Medical Technology Co EBIT?

Zhejiang Taimei Medical Technology Co FRA:A2V +1.69% 11 EBIT is €-6.03 Mil as of Dec. 2025. GuruFocus rates FRA:A2V with a GF Score™ of 11/100. The stock has 4 warning signs investors should review.

Zhejiang Taimei Medical Technology Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €-2.56 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €-6.03 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Zhejiang Taimei Medical Technology Co's annualized ROC % for the quarter that ended in Dec. 2025 was -20.21%. Zhejiang Taimei Medical Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -138.71%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Zhejiang Taimei Medical Technology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -2.87%.

Zhejiang Taimei Medical Technology Co  (FRA:A2V) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Zhejiang Taimei Medical Technology Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-5.04 * ( 1 - 0% )/( (24.035 + 25.85)/ 2 )
=-5.04/24.9425
=-20.21 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=183.354 - 20.55 - ( 138.769 - max(0, 30.356 - 171.726+138.769))
=24.035

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=188.707 - 24.366 - ( 144.519 - max(0, 39.765 - 178.256+144.519))
=25.85

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Zhejiang Taimei Medical Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-5.126/( ( (3.395 + max(1.289, 0)) + (2.707 + max(-1.661, 0)) )/ 2 )
=-5.126/( ( 4.684 + 2.707 )/ 2 )
=-5.126/3.6955
=-138.71 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(19.917 + 0 + 10.424) - (20.55 + 0 + 8.502)
=1.289

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(21.783 + 0 + 9.281) - (24.366 + 0 + 8.359)
=-1.661

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Zhejiang Taimei Medical Technology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-6.032/210.441
=-2.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Taimei Medical Technology Co EBIT Related Terms

Zhejiang Taimei Medical Technology Co EBIT Historical Data

* Premium members only.

The historical data trend for Zhejiang Taimei Medical Technology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Taimei Medical Technology Co EBIT Chart

Zhejiang Taimei Medical Technology Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
-66.26 -56.86 -45.58 -28.42 -6.05

Zhejiang Taimei Medical Technology Co Semi-Annual Data
Dec21 Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial 0.00 -22.42 -5.46 -3.47 -2.56

FRA:A2V vs VEEV, BTSG, HQY: EBIT Comparison

For the Health Information Services subindustry, Zhejiang Taimei Medical Technology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zhejiang Taimei Medical Technology Co EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Zhejiang Taimei Medical Technology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Zhejiang Taimei Medical Technology Co's EV-to-EBIT falls into.


FRA:A2V
11GF Score
Zhejiang Taimei Medical Technology Co Ltd FRA:A2V
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang Taimei Medical Technology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-6.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-6.03 Mil mean?
Zhejiang Taimei Medical Technology Co (FRA:A2V) has a EBIT of €-6.03 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Zhejiang Taimei Medical Technology Co.
Is Zhejiang Taimei Medical Technology Co's EBIT too high?
Zhejiang Taimei Medical Technology Co's current EBIT is €-6.03 Mil. Overall, Zhejiang Taimei Medical Technology Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Taimei Medical Technology Co's EBIT compare to VEEV and BTSG?
Zhejiang Taimei Medical Technology Co's EBIT of €-6.03 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Zhejiang Taimei Medical Technology Co. Zhejiang Taimei Medical Technology Co's current EBIT is €-6.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Taimei Medical Technology Co stock overvalued right now?
Zhejiang Taimei Medical Technology Co (FRA:A2V) has a current EBIT of €-6.03 Mil. The current EBIT is €-6.03 Mil. Zhejiang Taimei Medical Technology Co's overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Zhejiang Taimei Medical Technology Co (FRA:A2V), the current EBIT is €-6.03 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zhejiang Taimei Medical Technology Co Business Description

Other Exchanges 02576:Hong Kong
Address 36 Changsheng South Road, 3rd Floor, Building 9, Smart Industry Innovation Park, Zhejiang Province, Jiaxing, CHN
Zhejiang Taimei Medical Technology Co Ltd is a digital solution provider focused on the pharmaceutical and medical device industry in China. It designs and delivers industry-specific software and digital services that facilitate research and development (R&D) and the commercialization of pharmaceuticals and medical devices. The software it offers is cloud-based, allowing users to access it from various devices at any time over the internet, without the need for software installation and maintenance on their devices. It has a geographical presence in Mainland China, the United States, Singapore, Korea, and Others.
11GF Score

Get the complete analysis for FRA:A2V

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.60
Price